Katsunobu Hagihara

77MO Raludotatug deruxtecan (R-DXd) monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): Subgroup analysis of a phase I study

Katherine Moore, Alexander V. Philipovskiy, Kazuki Sudo, Kenichi Harano et autres

Relapsed OC remains difficult to manage, underscoring the need for new treatment options, even in pts with PSOC. Cadherin 6 (CDH6), a mediator of cell–cell adhesion, is expressed in 65–85% of OCs and is associated with poor prognosis. The CDH6–directed antibody–drug conjugate …

us, jp, gb (code pays fourni par la source)

Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study

Kathleen N. Moore, Alexander V. Philipovskiy, Kenichi Harano, Brian I. Rini et autres

us, jp (code pays fourni par la source)

Supplemental material and method from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi et autres

Cell line and patient-derived xenograft studies

Supplemental Table 1 from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi et autres

Histopathological findings in the intestines, bone marrow and lung in the repeated dose study in monkeys

Data from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi et autres

Abstract Purpose: An anti-HER2 antibody–drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclinical pharmacologic profile was assessed. Experimental Design: In vitro and in vivo pharmacologic activities of DS-8201a were evaluated and …

Data from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi et autres

Abstract Purpose: An anti-HER2 antibody–drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclinical pharmacologic profile was assessed. Experimental Design: In vitro and in vivo pharmacologic activities of DS-8201a were evaluated and …

Supplemental Table 1 from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi et autres

Histopathological findings in the intestines, bone marrow and lung in the repeated dose study in monkeys

Supplemental material and method from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi et autres

Cell line and patient-derived xenograft studies

Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy

Li Zhang, Jason Cham, James V. Cooley, Tao He et autres

Neoadjuvant immunotherapy can induce immune responses within the tumor microenvironment. Gene expression can be used to assess responses with limited amounts of conventionally-fixed patient-derived samples. We aim to assess the cross-platform concordance of immune-related gene expression data. We performed comparisons across three …

us (code pays fourni par la source)

Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice

Hiromi Okamoto, Masataka Oitate, Katsunobu Hagihara, Hideyuki Shiozawa et autres

Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7–8 with the topoisomerase I inhibitor DXd. In this study, we investigated the pharmacokinetics (PK), biodistribution, catabolism, and excretion profiles of T-DXd in …

jp (code pays fourni par la source)

Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Manabu Abe, Motoko Nagata, Kumiko Koyama, Satoru Yasuda et autres

Abstract Background of the study: [fam-] trastuzumab deruxtecan (DS-8201a) is a HER2-targeting antibody-drug conjugate (ADC) with a humanized anti-HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a peptide-based cleavable linker. [fam-] trastuzumab deruxtecan has been shown to be highly …

jp, us (code pays fourni par la source)

Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Manabu Abe, Motoko Nagata, Kumiko Koyama, Satoru Yasuda et autres

Background of the study: [fam-] trastuzumab deruxtecan (DS-8201a) is a HER2-targeting antibody-drug conjugate (ADC) with a humanized anti-HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a peptide-based cleavable linker. [fam-] trastuzumab deruxtecan has been shown to be highly effective …

jp, us (code pays fourni par la source)